Literature DB >> 10626821

The novel retinoid 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphtalene carboxylic acid can trigger apoptosis through a mitochondrial pathway independent of the nucleus.

P Marchetti1, N Zamzami, B Joseph, S Schraen-Maschke, C Méreau-Richard, P Costantini, D Métivier, S A Susin, G Kroemer, P Formstecher.   

Abstract

The novel retinoid 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphtalene carboxylic acid (AHPN/CD437), a retinoic acid receptor (RAR)gamma activator, has been found to inhibit the growth and to induce apoptosis of a wide variety of malignant cell types including solid tumors and various leukemias. Interestingly, CD437 is able to induce apoptosis in some all-trans-retinoic acid (ATRA)-resistant models. In a number of experimental systems, the early apoptotic stage that precedes nuclear chromatinolysis consists in mitochondrial alterations, including a disruption of the inner mitochondrial transmembrane potential (delta(psi)m) mediated by the mitochondrial permeability transition (MPT). Similarly CD437 causes RPMI 8226, a human myeloma cell line, to undergo a rapid delta(psi)m disruption that precedes other apoptotic alterations such as the generation of reactive oxygen species and DNA fragmentation. The same sequence of events is observed during the CD437-induced apoptosis in L363, a RARgamma-negative human myeloma cell line, as well as RPMI 8226 cytoplasts (anucleate cells). Indeed, RPMI 8226 cells and cytoplasts manifest a similar degree in delta(psi)m loss, phosphatidylserine exposure, and caspase activation in response to CD437, which indicates that nuclear effects cannot account for the apoptogenic potential of CD437. The mitochondrial release of cytochrome c, the activation of caspases as well as nuclear signs of CD437-induced apoptosis are fully prevented by the MPT inhibitory compound cyclosporin A. Purified mitochondria can be directly induced to undergo MPT with CD437 but not with ATRA. In a cell-free in vitro system consisting of exposing mitochondrial supernatants to isolated nuclei, only supernatants from CD437-treated mitochondria provoke chromatin condensation, whereas supernatants from mitochondria treated with ATRA, or with the combination of CD437 and cyclosporin A, remain inactive. In conclusion, these results suggest that the rapid execution of CD437-induced apoptosis is a nucleus-independent (and probably RARgamma-independent) phenomenon involving mitochondria and MPT.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10626821

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  17 in total

1.  Enhanced cell cycle perturbation and apoptosis mediate the synergistic effects of ST1926 and ATRA in neuroblastoma preclinical models.

Authors:  Angela Maria Di Francesco; Paolo Ubezio; Anna Rita Torella; Daniela Meco; Filomena Pierri; Giuseppe Barone; Gabriella Cusano; Claudio Pisano; Maurizio D'Incalci; Riccardo Riccardi
Journal:  Invest New Drugs       Date:  2011-06-03       Impact factor: 3.850

2.  Molecular recognition and enhancement of aqueous solubility and bioactivity of CD437 by β-cyclodextrin.

Authors:  Robert J Mishur; Matthew E Griffin; Cooper H Battle; Bin Shan; Janarthanan Jayawickramarajah
Journal:  Bioorg Med Chem Lett       Date:  2010-11-21       Impact factor: 2.823

Review 3.  Mitochondria: a target for cancer therapy.

Authors:  Jeffrey S Armstrong
Journal:  Br J Pharmacol       Date:  2006-02       Impact factor: 8.739

Review 4.  Mitochondrial medicine: pharmacological targeting of mitochondria in disease.

Authors:  J S Armstrong
Journal:  Br J Pharmacol       Date:  2007-05-21       Impact factor: 8.739

5.  Highly twisted adamantyl arotinoids: synthesis, antiproliferative effects and RXR transactivation profiles.

Authors:  Santiago Pérez-Rodríguez; Maria A Ortiz; Raquel Pereira; Fátima Rodríguez-Barrios; Angel R de Lera; F Javier Piedrafita
Journal:  Eur J Med Chem       Date:  2009-01-20       Impact factor: 6.514

Review 6.  The lipophilic bullet hits the targets: medicinal chemistry of adamantane derivatives.

Authors:  Lukas Wanka; Khalid Iqbal; Peter R Schreiner
Journal:  Chem Rev       Date:  2013-02-25       Impact factor: 60.622

7.  Adamantyl arotinoids that inhibit IκB kinase α and IκB kinase β.

Authors:  Paula Lorenzo; María A Ortiz; Rosana Alvarez; F Javier Piedrafita; Angel R de Lera
Journal:  ChemMedChem       Date:  2013-05-07       Impact factor: 3.466

8.  Inhibition of IκB kinase-β and IκB kinase-α by heterocyclic adamantyl arotinoids.

Authors:  José García-Rodríguez; Santiago Pérez-Rodríguez; María A Ortiz; Raquel Pereira; Angel R de Lera; F Javier Piedrafita
Journal:  Bioorg Med Chem       Date:  2014-01-10       Impact factor: 3.641

9.  Adamantyl-substituted retinoid-related molecules bind small heterodimer partner and modulate the Sin3A repressor.

Authors:  Lulu Farhana; Marcia I Dawson; Mark Leid; Li Wang; David D Moore; Gang Liu; Zeben Xia; Joseph A Fontana
Journal:  Cancer Res       Date:  2007-01-01       Impact factor: 12.701

Review 10.  Mitochondrial metabolism inhibitors for cancer therapy.

Authors:  Emma E Ramsay; Philip J Hogg; Pierre J Dilda
Journal:  Pharm Res       Date:  2011-09-15       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.